Skip to main content

Balchem Announces Dividend Increase and Stock Buyback

Tipranks - Thu Dec 11, 2025

Claim 50% Off TipRanks Premium and Invest with Confidence

Balchem ( (BCPC) ) has provided an announcement.

On December 9, 2025, Balchem Corporation’s Board of Directors declared a dividend of $0.96 per share, marking a 10.3% increase from the previous year, payable on January 20, 2026. Additionally, the Board approved a new stock repurchase program allowing the repurchase of up to 4 million shares, replacing the previous program, with no expiration date and flexible execution, reflecting confidence in the company’s long-term strategies.

The most recent analyst rating on (BCPC) stock is a Hold with a $162.00 price target. To see the full list of analyst forecasts on Balchem stock, see the BCPC Stock Forecast page.

Spark’s Take on BCPC Stock

According to Spark, TipRanks’ AI Analyst, BCPC is a Outperform.

Balchem Corporation’s overall stock score of 80 reflects its strong financial performance and positive earnings call, which highlight record-breaking growth and strategic initiatives. The technical analysis suggests potential short-term volatility, and the valuation indicates the stock may be overvalued. However, the company’s robust financial health and positive outlook support a favorable stock assessment.

To see Spark’s full report on BCPC stock, click here.

More about Balchem

Balchem Corporation develops, manufactures, and markets specialty ingredients aimed at enhancing health and well-being across various industries globally. The company operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, offering solutions for the food, supplement, pharmaceutical, animal health, and agricultural markets.

Average Trading Volume: 171,753

Technical Sentiment Signal: Hold

Current Market Cap: $4.77B

Find detailed analytics on BCPC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.